Di Cesare Mariachiara, Jarvis Jordan D, Scarlatescu Oana, Leng Xinyi, Zaidel Ezequiel J, Burrone Esteban, Eiselé Jean-Luc, Prabhakaran Dorairaj, Sliwa Karen
Middlesex University, London, GB.
London School of Hygiene and Tropical Medicine, London, GB.
Glob Heart. 2020 Oct 6;15(1):67. doi: 10.5334/gh.774.
The introduction of non-vitamin K antagonists oral anticoagulants, a class of medicines which includes dabigatran, apixaban, edoxaban and rivaroxaban, has resulted in improvements in the safety and efficacy of non valvular atrial fibrillation treatment for stroke prevention, with significant reductions in stroke, intracranial haemorrhage, and mortality. For these reasons, a team of World Heart Federation Emerging Leaders led efforts to add non-vitamin K antagonists oral anticoagulants to the World Health Organization's Model List of Essential Medicines in 2019. Following the inclusion of this class of medicines in the Essential Medicines List, this editorial proposes several recommendations to improve the accessibility, affordability and acceptability of non-vitamin K oral anticoagulants, especially in low- and middle-income settings, in order to successfully manage non-valvular atrial fibrillation and to lower the risk of stroke.
非维生素K拮抗剂口服抗凝药（包括达比加群、阿哌沙班、依度沙班和利伐沙班）的引入，改善了非瓣膜性心房颤动预防中风治疗的安全性和有效性，显著降低了中风、颅内出血和死亡率。基于这些原因，世界心脏联盟新兴领导者团队在2019年努力将非维生素K拮抗剂口服抗凝药纳入世界卫生组织基本药物示范清单。在这类药物被列入基本药物清单之后，本社论提出了若干建议，以提高非维生素K口服抗凝药的可及性、可负担性和可接受性，特别是在低收入和中等收入环境中，以便成功管理非瓣膜性心房颤动并降低中风风险。
